Journal: Computational biology and chemistry

Article Title: Dual computational and biological assessment of some promising nucleoside analogs against the COVID-19-Omicron variant.

doi: 10.1016/j.compbiolchem.2022.107768

Figure Lengend Snippet: Fig. 2. RMSD trajectories (during a simulation period of 100 ns) of the α-carbon of amino acid residues of the protein (blue color) and the ligand (maroon color) in the protein-ligand complexes of the two NAs, riboprine and forodesine, and the two reference drugs, remdesivir and molnupiravir, respectively, with: (A) SARS-CoV- 2 RdRp "nsp12" enzyme cocrystallized with its protein cofactors nsp7 and nsp8 (PDB ID: 7BV2). (B) SARS-CoV-2 ExoN "nsp14" enzyme cocrystallized with its protein cofactor nsp10 (PDB ID: 7MC6). For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.

Article Snippet: While forodesine (Immucillin-H, CAS Registry Number: 209799–67–7), nelarabine (Arranon, CAS Registry Number: 121032–29–9), tecadenoson (CVT-510, CAS Registry Number: 204512–90–3), maribavir (1263W94, CAS Registry Number: 176161–24–3), vidarabine (Arabinosyladenine "Ara-A", CAS Registry Number: 5536–17–4), remdesivir (GS-5734, CAS Registry Number: 1809249–37–3), and molnupiravir (EIDD-2801, CAS Registry Number: 2349386–89–4) were purchased from Biosynth Carbosynth (Carbosynth Ltd., Berkshire, U.K.) (for forodesine, Product Code: MD11591, Purity: ≥ 98 %; for nelarabine, Product Code: NN26176, Purity: ≥ 98 %; for tecadenoson, Product Code: EIA51290, Purity: ≥ 98 %; for maribavir, Product Code: AM178224, Purity: ≥ 98 %; for vidarabine, Product Code: NA06007, Purity: ≥ 98 %; for remdesivir, Product Code: AG170167, Purity: ≥ 98 %; for molnupiravir, Product Code: AE176721, Purity: ≥ 98 %).

Techniques:

Journal: Computational biology and chemistry

Article Title: Dual computational and biological assessment of some promising nucleoside analogs against the COVID-19-Omicron variant.

doi: 10.1016/j.compbiolchem.2022.107768

Figure Lengend Snippet: Fig. 3. RMSF trajectories (along the different residue regions) of the α-carbon of amino acid residues of the protein in the protein-ligand complexes of the two NAs, riboprine and forodesine, and the two reference drugs, remdesivir and molnupiravir, respectively, with: (A) SARS-CoV-2 RdRp "nsp12" enzyme cocrystallized with its protein cofactors nsp7 and nsp8 (PDB ID: 7BV2). (B) SARS-CoV-2 ExoN "nsp14" enzyme cocrystallized with its protein cofactor nsp10 (PDB ID: 7MC6).

Article Snippet: While forodesine (Immucillin-H, CAS Registry Number: 209799–67–7), nelarabine (Arranon, CAS Registry Number: 121032–29–9), tecadenoson (CVT-510, CAS Registry Number: 204512–90–3), maribavir (1263W94, CAS Registry Number: 176161–24–3), vidarabine (Arabinosyladenine "Ara-A", CAS Registry Number: 5536–17–4), remdesivir (GS-5734, CAS Registry Number: 1809249–37–3), and molnupiravir (EIDD-2801, CAS Registry Number: 2349386–89–4) were purchased from Biosynth Carbosynth (Carbosynth Ltd., Berkshire, U.K.) (for forodesine, Product Code: MD11591, Purity: ≥ 98 %; for nelarabine, Product Code: NN26176, Purity: ≥ 98 %; for tecadenoson, Product Code: EIA51290, Purity: ≥ 98 %; for maribavir, Product Code: AM178224, Purity: ≥ 98 %; for vidarabine, Product Code: NA06007, Purity: ≥ 98 %; for remdesivir, Product Code: AG170167, Purity: ≥ 98 %; for molnupiravir, Product Code: AE176721, Purity: ≥ 98 %).

Techniques: Residue

Journal: Computational biology and chemistry

Article Title: Dual computational and biological assessment of some promising nucleoside analogs against the COVID-19-Omicron variant.

doi: 10.1016/j.compbiolchem.2022.107768

Figure Lengend Snippet: Fig. 4. Collective post-MD simulation analysis of the protein-ligand complexes properties (RMSD, rGyr, MolSA, SASA, and PSA) of the two NAs, riboprine and forodesine, and the two reference drugs, remdesivir and molnupiravir, respectively, with: (A) SARS-CoV-2 RdRp "nsp12" enzyme cocrystallized with its protein cofactors nsp7 and nsp8 (PDB ID: 7BV2). (B) SARS-CoV-2 ExoN "nsp14" enzyme cocrystallized with its protein cofactor nsp10 (PDB ID: 7MC6).

Article Snippet: While forodesine (Immucillin-H, CAS Registry Number: 209799–67–7), nelarabine (Arranon, CAS Registry Number: 121032–29–9), tecadenoson (CVT-510, CAS Registry Number: 204512–90–3), maribavir (1263W94, CAS Registry Number: 176161–24–3), vidarabine (Arabinosyladenine "Ara-A", CAS Registry Number: 5536–17–4), remdesivir (GS-5734, CAS Registry Number: 1809249–37–3), and molnupiravir (EIDD-2801, CAS Registry Number: 2349386–89–4) were purchased from Biosynth Carbosynth (Carbosynth Ltd., Berkshire, U.K.) (for forodesine, Product Code: MD11591, Purity: ≥ 98 %; for nelarabine, Product Code: NN26176, Purity: ≥ 98 %; for tecadenoson, Product Code: EIA51290, Purity: ≥ 98 %; for maribavir, Product Code: AM178224, Purity: ≥ 98 %; for vidarabine, Product Code: NA06007, Purity: ≥ 98 %; for remdesivir, Product Code: AG170167, Purity: ≥ 98 %; for molnupiravir, Product Code: AE176721, Purity: ≥ 98 %).

Techniques:

Journal: Computational biology and chemistry

Article Title: Dual computational and biological assessment of some promising nucleoside analogs against the COVID-19-Omicron variant.

doi: 10.1016/j.compbiolchem.2022.107768

Figure Lengend Snippet: Fig. 5. Histograms of the protein-ligand interactions fractions throughout the simulative interaction trajectories of the two NAs, riboprine and forodesine, and the two reference drugs, remdesivir and molnupiravir, respectively, with: (A) SARS-CoV-2 RdRp "nsp12" enzyme cocrystallized with its protein cofactors nsp7 and nsp8 (PDB ID: 7BV2). (B) SARS-CoV-2 ExoN "nsp14" enzyme cocrystallized with its protein cofactor nsp10 (PDB ID: 7MC6).

Article Snippet: While forodesine (Immucillin-H, CAS Registry Number: 209799–67–7), nelarabine (Arranon, CAS Registry Number: 121032–29–9), tecadenoson (CVT-510, CAS Registry Number: 204512–90–3), maribavir (1263W94, CAS Registry Number: 176161–24–3), vidarabine (Arabinosyladenine "Ara-A", CAS Registry Number: 5536–17–4), remdesivir (GS-5734, CAS Registry Number: 1809249–37–3), and molnupiravir (EIDD-2801, CAS Registry Number: 2349386–89–4) were purchased from Biosynth Carbosynth (Carbosynth Ltd., Berkshire, U.K.) (for forodesine, Product Code: MD11591, Purity: ≥ 98 %; for nelarabine, Product Code: NN26176, Purity: ≥ 98 %; for tecadenoson, Product Code: EIA51290, Purity: ≥ 98 %; for maribavir, Product Code: AM178224, Purity: ≥ 98 %; for vidarabine, Product Code: NA06007, Purity: ≥ 98 %; for remdesivir, Product Code: AG170167, Purity: ≥ 98 %; for molnupiravir, Product Code: AE176721, Purity: ≥ 98 %).

Techniques:

Journal: Computational biology and chemistry

Article Title: Dual computational and biological assessment of some promising nucleoside analogs against the COVID-19-Omicron variant.

doi: 10.1016/j.compbiolchem.2022.107768

Figure Lengend Snippet: Fig. 6. Plots of the distribution of the total number of interactions (contacts) in each trajectory framework of the protein-ligand complexes of the two NAs, riboprine and forodesine, and the two reference drugs, remdesivir and molnupiravir, respectively, with: (A) SARS-CoV-2 RdRp "nsp12" enzyme cocrystallized with its protein cofactors nsp7 and nsp8 (PDB ID: 7BV2). (B) SARS-CoV-2 ExoN "nsp14" enzyme cocrystallized with its protein cofactor nsp10 (PDB ID: 7MC6).

Article Snippet: While forodesine (Immucillin-H, CAS Registry Number: 209799–67–7), nelarabine (Arranon, CAS Registry Number: 121032–29–9), tecadenoson (CVT-510, CAS Registry Number: 204512–90–3), maribavir (1263W94, CAS Registry Number: 176161–24–3), vidarabine (Arabinosyladenine "Ara-A", CAS Registry Number: 5536–17–4), remdesivir (GS-5734, CAS Registry Number: 1809249–37–3), and molnupiravir (EIDD-2801, CAS Registry Number: 2349386–89–4) were purchased from Biosynth Carbosynth (Carbosynth Ltd., Berkshire, U.K.) (for forodesine, Product Code: MD11591, Purity: ≥ 98 %; for nelarabine, Product Code: NN26176, Purity: ≥ 98 %; for tecadenoson, Product Code: EIA51290, Purity: ≥ 98 %; for maribavir, Product Code: AM178224, Purity: ≥ 98 %; for vidarabine, Product Code: NA06007, Purity: ≥ 98 %; for remdesivir, Product Code: AG170167, Purity: ≥ 98 %; for molnupiravir, Product Code: AE176721, Purity: ≥ 98 %).

Techniques:

Journal: Computational biology and chemistry

Article Title: Dual computational and biological assessment of some promising nucleoside analogs against the COVID-19-Omicron variant.

doi: 10.1016/j.compbiolchem.2022.107768

Figure Lengend Snippet: Fig. 7. Cytotoxicity graphs obtained in the current study for: (a) Riboprine, (b) Forodesine, (c) Nelarabine, (d) Tecadenoson, (e) Maribavir, (f) Vidarabine, (g) Remdesivir, (h) Molnupiravir, and (i) DMSO.

Article Snippet: While forodesine (Immucillin-H, CAS Registry Number: 209799–67–7), nelarabine (Arranon, CAS Registry Number: 121032–29–9), tecadenoson (CVT-510, CAS Registry Number: 204512–90–3), maribavir (1263W94, CAS Registry Number: 176161–24–3), vidarabine (Arabinosyladenine "Ara-A", CAS Registry Number: 5536–17–4), remdesivir (GS-5734, CAS Registry Number: 1809249–37–3), and molnupiravir (EIDD-2801, CAS Registry Number: 2349386–89–4) were purchased from Biosynth Carbosynth (Carbosynth Ltd., Berkshire, U.K.) (for forodesine, Product Code: MD11591, Purity: ≥ 98 %; for nelarabine, Product Code: NN26176, Purity: ≥ 98 %; for tecadenoson, Product Code: EIA51290, Purity: ≥ 98 %; for maribavir, Product Code: AM178224, Purity: ≥ 98 %; for vidarabine, Product Code: NA06007, Purity: ≥ 98 %; for remdesivir, Product Code: AG170167, Purity: ≥ 98 %; for molnupiravir, Product Code: AE176721, Purity: ≥ 98 %).

Techniques:

Journal: Advanced biology

Article Title: Predicting Clinical Outcomes of SARS-CoV-2 Drug Efficacy with a High-Throughput Human Airway Microphysiological System.

doi: 10.1002/adbi.202300511

Figure Lengend Snippet: Figure 3. Differential response of PREDICT96-ALI to antiviral drugs. Comparison between the antiviral effects of six drug compounds, nirmatrelvir, molnupiravir, remdesivir, calpeptin, fluvoxamine, and amodiaquine, against SARS-CoV-2 infection in tissue from donor 0 4401 grown in PREDICT96-ALI. A) Effects of nirmatrelvir, molnupiravir, remdesivir, and calpeptin against SARS-CoV-2 USA-WA1/2020. B) Table shows inter- and intra-plate variability from PREDICT96-ALI over experimental time course (SARS-CoV-2 USA-WA1/2020). Coefficients of variation (% CV) were calculated from viral genome quantification data for each condition (n = 3 or 4 individual tissue devices per condition, 18 conditions total) and averaged across conditions at each time point. Plate 1 (top row) corresponds to the datasets represented in panel A, plate 2 is an independent experiment (data not shown). C) Image quantification of SARS-CoV-2 infected tissues nucleocapsid positive (+) cells shows tissue response to 5 drug compounds 6 days post inoculation (d.p.i.) of SARS-CoV-2 USA-WA1/2020 infection in donor 0 4401. Briefly, in tissues stained for nuclei (Hoechst) and SARS-CoV-2 nucleocapsid (N) protein, the Celigo software was used to quantify the percentage of nuclei corresponding cells to cell positive for the N. (D) Effects of nirmatrelvir, molnupiravir, remdesivir, amodiaquine and fluvoxamine against SARS-CoV-2 Omicron variant. (E) The table shows inter- and intra-plate variability as % CV from PREDICT96-ALI over experimental time course (Omicron variant). Plate 1 (top row) corresponds to the datasets represented in panel D, plate 2 is an independent experiment (data not shown). In panels (A) and (D): Antiviral drugs were diluted in media and added 2 h after infection and again on at 2 and 4 d.p.i. at the concentrations indicated. Apical sides of tissues were washed with HBSS to collect viral supernatant from which SARS-CoV-2 viral genomes were quantified by RT-qPCR. Data presented as mean ± standard error of the mean. n = 4 tissue devices per condition. Data collected from the same experiment panel A displayed in panel C and representative of 2 independent experiments. All bar graphs show mean ± standard deviation. Statistical significance determined by a two-way analysis of variance (ANOVA) with Dunnett’s test for multiple comparisons (comparing to infected vehicle control (A and D) or infected/untreated C)): p > 0.05; *p ≤0.05; **p ≤0.01; ***p ≤0.001; ****p ≤0.0001. Unlabeled lines indicate no significant difference. See also Figure S2 (Supporting Information).

Article Snippet: Antiviral Drug Dosing: Nirmatrelvir (MedChemExpress), PF-00835231 (MedChemExpress), Molnupiravir (Tocris Bioscience), Calpeptin (Tocris Bioscience) and Remdesivir (Tocris Bioscience), Fluvoxamine maleate (Selleck Chemicals), and Amodiaquine dihydrochloride dihydrate (Millipore-Sigma) were used in anti-viral screens performed on PREDICT96-ALI tissue.

Techniques: Comparison, Infection, Staining, Software, Variant Assay, Quantitative RT-PCR, Standard Deviation, Control

Journal: Diabetes & Metabolic Syndrome

Article Title: An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19 ☆

doi: 10.1016/j.dsx.2022.102396

Figure Lengend Snippet: Results from molnupiravir MOVe-OUT trial in adults with mild-to-moderate COVID-19 [ [14] , [21] , [22] , [23] , [24] ].

Article Snippet: For example-primary outcome was all-cause hospitalization or death for molnupiravir (MOVe-OUT), nirmatrelvir-ritonavir (EPIC-HR) and sotrovimab (COMET-ICE) while it was COVID-19-related hospitalization or death for casirivimab–imdevimab (REGEN-COV), bamlanivimab–etesevimab (BLAZE-1) and remdesivir (PINETREE).

Techniques:

Journal: Diabetes & Metabolic Syndrome

Article Title: An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19 ☆

doi: 10.1016/j.dsx.2022.102396

Figure Lengend Snippet: Subgroups who appeared to have no benefit in hospitalization or death through day 29 with molnupiravir over placebo [ [14] , [21] , [22] , [23] , [24] ].

Article Snippet: For example-primary outcome was all-cause hospitalization or death for molnupiravir (MOVe-OUT), nirmatrelvir-ritonavir (EPIC-HR) and sotrovimab (COMET-ICE) while it was COVID-19-related hospitalization or death for casirivimab–imdevimab (REGEN-COV), bamlanivimab–etesevimab (BLAZE-1) and remdesivir (PINETREE).

Techniques:

Journal: Diabetes & Metabolic Syndrome

Article Title: An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19 ☆

doi: 10.1016/j.dsx.2022.102396

Figure Lengend Snippet: Comparative efficacy data of EUA/authorized # drugs for COVID-19 [ [14] , [28] , [29] , [30] , [31] , [32] ].

Article Snippet: For example-primary outcome was all-cause hospitalization or death for molnupiravir (MOVe-OUT), nirmatrelvir-ritonavir (EPIC-HR) and sotrovimab (COMET-ICE) while it was COVID-19-related hospitalization or death for casirivimab–imdevimab (REGEN-COV), bamlanivimab–etesevimab (BLAZE-1) and remdesivir (PINETREE).

Techniques: In Vitro

Journal: Diabetes & Metabolic Syndrome

Article Title: An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19 ☆

doi: 10.1016/j.dsx.2022.102396

Figure Lengend Snippet:

Article Snippet: For example-primary outcome was all-cause hospitalization or death for molnupiravir (MOVe-OUT), nirmatrelvir-ritonavir (EPIC-HR) and sotrovimab (COMET-ICE) while it was COVID-19-related hospitalization or death for casirivimab–imdevimab (REGEN-COV), bamlanivimab–etesevimab (BLAZE-1) and remdesivir (PINETREE).

Techniques: Infection

Journal: Diabetes & Metabolic Syndrome

Article Title: An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19 ☆

doi: 10.1016/j.dsx.2022.102396

Figure Lengend Snippet:

Article Snippet: For example-primary outcome was all-cause hospitalization or death for molnupiravir (MOVe-OUT), nirmatrelvir-ritonavir (EPIC-HR) and sotrovimab (COMET-ICE) while it was COVID-19-related hospitalization or death for casirivimab–imdevimab (REGEN-COV), bamlanivimab–etesevimab (BLAZE-1) and remdesivir (PINETREE).

Techniques: Bioprocessing

Journal: Diabetes & Metabolic Syndrome

Article Title: An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19 ☆

doi: 10.1016/j.dsx.2022.102396

Figure Lengend Snippet:

Article Snippet: For example-primary outcome was all-cause hospitalization or death for molnupiravir (MOVe-OUT), nirmatrelvir-ritonavir (EPIC-HR) and sotrovimab (COMET-ICE) while it was COVID-19-related hospitalization or death for casirivimab–imdevimab (REGEN-COV), bamlanivimab–etesevimab (BLAZE-1) and remdesivir (PINETREE).

Techniques: Infection

Journal: Diabetes & Metabolic Syndrome

Article Title: Molnupiravir in COVID-19: A systematic review of literaturef

doi: 10.1016/j.dsx.2021.102329

Figure Lengend Snippet: Mechanism of action (schematic representation) of molnupiravir against SARS-CoV-2 (works by inducing mutagenesis in viral RNA) as compared with remdesivir (works by stalling RdRp in turn causing chain termination of newly formed RNA strand) and favipiravir (works by slowing/stalling RdRp causing chain termination or inducing mutagenesis or both).

Article Snippet: Several other ongoing studies of molnupiravir in mild COVID-19 by other Indian pharmaceutical companies such as Aurobindo pharma, Telangana, India (CTRI/2021/07/034588); NATCO pharma, Hyderabad, India (CTRI/2021/05/033693); MSN Laboratories, Hyderabad, India (CTRI/2021/05/033904); BDR Pharmaceuticals, Mumbai, India (CTRI/2021/06/034130); Dr. Reddys Lab, Hyderabad, India (CTRI/2021/06/033938) and Stride Pharma, Bengaluru, India (CTRI/2021/06/034015) are yet to report their results.

Techniques: Mutagenesis

Journal: Diabetes & Metabolic Syndrome

Article Title: Molnupiravir in COVID-19: A systematic review of literaturef

doi: 10.1016/j.dsx.2021.102329

Figure Lengend Snippet: A. Published and unpublished (interim results), B. Stopped, and C. Ongoing studies with molnupiravir in COVID-19.

Article Snippet: Several other ongoing studies of molnupiravir in mild COVID-19 by other Indian pharmaceutical companies such as Aurobindo pharma, Telangana, India (CTRI/2021/07/034588); NATCO pharma, Hyderabad, India (CTRI/2021/05/033693); MSN Laboratories, Hyderabad, India (CTRI/2021/05/033904); BDR Pharmaceuticals, Mumbai, India (CTRI/2021/06/034130); Dr. Reddys Lab, Hyderabad, India (CTRI/2021/06/033938) and Stride Pharma, Bengaluru, India (CTRI/2021/06/034015) are yet to report their results.

Techniques: Clinical Proteomics, Concentration Assay

Journal: Pharmacoeconomics

Article Title: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US

doi: 10.1007/s40273-022-01168-0

Figure Lengend Snippet: Efficacy of molnupiravir based on the MOVe-OUT trial

Article Snippet: While the Institute for Clinical and Economic Review’s model structure was similar to the structure of the current study’s model, in that draft report the ICER of molnupiravir versus usual care was estimated at $55,000 per QALY gained.

Techniques:

Journal: Pharmacoeconomics

Article Title: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US

doi: 10.1007/s40273-022-01168-0

Figure Lengend Snippet: Overall QALY, cost, and ICER estimates for molnupiravir versus best supportive care, in the base-case analysis

Article Snippet: While the Institute for Clinical and Economic Review’s model structure was similar to the structure of the current study’s model, in that draft report the ICER of molnupiravir versus usual care was estimated at $55,000 per QALY gained.

Techniques:

Journal: Pharmacoeconomics

Article Title: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US

doi: 10.1007/s40273-022-01168-0

Figure Lengend Snippet: Disease outcomes

Article Snippet: While the Institute for Clinical and Economic Review’s model structure was similar to the structure of the current study’s model, in that draft report the ICER of molnupiravir versus usual care was estimated at $55,000 per QALY gained.

Techniques:

Journal: Pharmacoeconomics

Article Title: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US

doi: 10.1007/s40273-022-01168-0

Figure Lengend Snippet: Direct medical cost outcomes

Article Snippet: While the Institute for Clinical and Economic Review’s model structure was similar to the structure of the current study’s model, in that draft report the ICER of molnupiravir versus usual care was estimated at $55,000 per QALY gained.

Techniques:

Journal: Pharmacoeconomics

Article Title: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US

doi: 10.1007/s40273-022-01168-0

Figure Lengend Snippet: QALY outcomes

Article Snippet: While the Institute for Clinical and Economic Review’s model structure was similar to the structure of the current study’s model, in that draft report the ICER of molnupiravir versus usual care was estimated at $55,000 per QALY gained.

Techniques:

Journal: Pharmacoeconomics

Article Title: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US

doi: 10.1007/s40273-022-01168-0

Figure Lengend Snippet: Deterministic sensitivity analysis of the cost effectiveness of molnupiravir versus best supportive care. A negative ICER indicates that molnupiravir is dominating best supportive care (that is, leading to increased QALYs alongside reduced cost). The list of parameters presented in the DSA figure are based on the most impactful figures on the ICER value (top to bottom). ICU intensive care unit, MV mechanical ventilation, ICER incremental cost-effectiveness ratio, QALYs quality-adjusted life-years, DSA deterministic sensitivity analysis, CI confidence interval

Article Snippet: While the Institute for Clinical and Economic Review’s model structure was similar to the structure of the current study’s model, in that draft report the ICER of molnupiravir versus usual care was estimated at $55,000 per QALY gained.

Techniques:

Journal: Pharmacoeconomics

Article Title: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US

doi: 10.1007/s40273-022-01168-0

Figure Lengend Snippet: Probabilistic sensitivity analysis of the cost effectiveness of molnupiravir versus best supportive care. MOV molnupiravir treatment, Supp supportive (care), QALYs quality-adjusted life-years

Article Snippet: While the Institute for Clinical and Economic Review’s model structure was similar to the structure of the current study’s model, in that draft report the ICER of molnupiravir versus usual care was estimated at $55,000 per QALY gained.

Techniques:

Journal: Pharmacoeconomics

Article Title: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US

doi: 10.1007/s40273-022-01168-0

Figure Lengend Snippet:

Article Snippet: While the Institute for Clinical and Economic Review’s model structure was similar to the structure of the current study’s model, in that draft report the ICER of molnupiravir versus usual care was estimated at $55,000 per QALY gained.

Techniques:

Journal: Heliyon

Article Title: Garlic peel-based carbon quantum dots as a sustainable alternative for the sensitive and green spectrofluorometric quantification of molnupiravir in pharmaceutical capsules

doi: 10.1016/j.heliyon.2024.e40661

Figure Lengend Snippet: The fluorescence emission spectra of n-CQDs under varying concentrations of molnupiravir (0.5–30 μg/mL).

Article Snippet: Molnupiravir (99.80 %) was obtained from Eva Pharma Company (Cairo, Egypt).

Techniques: Fluorescence

Journal: Heliyon

Article Title: Garlic peel-based carbon quantum dots as a sustainable alternative for the sensitive and green spectrofluorometric quantification of molnupiravir in pharmaceutical capsules

doi: 10.1016/j.heliyon.2024.e40661

Figure Lengend Snippet: Recovery study using standard addition method.

Article Snippet: Molnupiravir (99.80 %) was obtained from Eva Pharma Company (Cairo, Egypt).

Techniques: Standard Addition, Concentration Assay

Journal: Heliyon

Article Title: Garlic peel-based carbon quantum dots as a sustainable alternative for the sensitive and green spectrofluorometric quantification of molnupiravir in pharmaceutical capsules

doi: 10.1016/j.heliyon.2024.e40661

Figure Lengend Snippet: A comparison between the GP-n-CQDs-QN-FL method and previously published methods.

Article Snippet: Molnupiravir (99.80 %) was obtained from Eva Pharma Company (Cairo, Egypt).

Techniques: Comparison, Formulation, Capsules, High Performance Thin Layer Chromatography